Heart Attack Risk May Drop For Millions With Wonder Drug That Reduces Cholesterol By 94%
Last Updated:
A US pharma company has developed an experimental drug that reduces lipoprotein(a) cholesterol by 94% with a single injection, offering new hope for heart attack prevention.
A revolutionary breakthrough in cardiovascular medicine has emerged from the United States, offering new hope for millions at risk of heart attacks due to stubborn cholesterol buildup. US pharmaceutical giant Eli Lilly has developed an experimental drug that reportedly slashes levels of a notoriously difficult form of cholesterol by an astonishing 94% – with a single injection.
The drug targets lipoprotein(a), or Lp(a), a genetic variant of cholesterol that behaves similarly to the more familiar LDL, often dubbed 'bad cholesterol." However, Lp(a) is markedly more dangerous. It adheres rapidly to arterial walls, accelerating the onset of atherosclerosis – the hardening and narrowing of arteries – and significantly increasing the risk of heart attack and stroke. Unlike LDL, which can often be managed through diet, lifestyle, and existing medications, Lp(a) has long resisted conventional treatment.
In a phase 2 clinical trial conducted by Eli Lilly, 141 participants received a 400 mg dose of the investigational drug. Another 69 individuals were administered a placebo. The results, published in the Journal of the American College of Cardiology, presented that within weeks, recipients of the drug showed a dramatic 94% reduction in Lp(a) levels, an effect that lasted up to six months with no reported side effects.
'This is a very promising development," said Dr Nitish Chandra, Principal Director at Fortis Escorts Heart Institute in Delhi. Until now, no therapy has effectively targeted Lp(a). Even blood-thinning medications can't remove this cholesterol from arteries and because Lp(a) is largely inherited, patients often face lifelong risk without any means of intervention, he said.
Currently, individuals with severe cholesterol blockage – more than 75% arterial narrowing – typically require a stent implantation to reduce the threat of a cardiac event. Conventional medications fail to dissolve cholesterol once it has significantly accumulated in the arteries, making prevention and early detection the primary strategies for at-risk patients. That may now change.
The Eli Lilly trial is only the beginning. While the reduction in Lp(a) is clear, whether it translates into fewer heart attacks or strokes remains to be proven. A larger, more comprehensive clinical trial is already underway, aiming to determine the drug's impact on long-term cardiovascular outcomes. Results from that trial are expected soon.
Meanwhile, Swiss pharmaceutical company Novartis is also in the race, developing a competing drug that requires monthly injections. Both treatments could potentially reshape the landscape of cardiac care, particularly for individuals with genetically elevated cholesterol who have, until now, had limited options.
First Published:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
2 days ago
- NDTV
New 'Living' Material That Sucks CO2 From Air Developed By Scientists
Scientists have developed a new 'photosynthetic' material capable of absorbing carbon dioxide (CO2) that can one day be used in buildings to fight climate change. The Swiss researchers have created the innovative substance using blue-green algae (cyanobacteria), which converts CO2, sunlight and water into oxygen and sugars through photosynthesis. Under specific nutrient conditions, it can also turn CO2 into sturdy, eco-friendly construction components and solid minerals such as limestone, providing permanent carbon storage while strengthening the material. "Cyanobacteria are among the oldest life forms in the world. They are highly efficient at photosynthesis and can utilise even the weakest light to produce biomass from CO2 and water," said Yifan Cui, one of the two lead authors of the study. The carrier material that harbours the living cells is a hydrogel - a gel made of cross-linked polymers with a high water content, according to the study published in the journal Nature Communications. To ensure that the cyanobacteria live as long as possible and remain efficient, the researchers optimised the geometry of the structures using 3D printing processes to increase the surface area, increase light penetration and promote the flow of nutrients. "We engineered printable photosynthetic living materials that were capable of carbon sequestration through biomass accumulation and inorganic carbonate precipitation," the study highlighted. Test results Test results showed that the material continuously absorbed CO2 over a 400-day period, with most of the "sequestered carbon stored in the stable mineral form". The total amount of CO2 sequestered through mineral formation after 400 days was 26 milligrams per gram of CO2 per gram of material. This is significantly more than many biological approaches and comparable to the chemical mineralisation of recycled concrete (around 7 mg CO2 per gram). "With minimum requirements of sunlight and atmospheric CO2, our photosynthetic living materials showed a consistent carbon sequestration efficiency throughout the entire incubation period," the researchers stated. At an art exhibition in Venice, Italy, the researchers presented the material in the form of two tree trunk-like objects that could absorb up to 18 kilograms of CO2 per year or as much as a 20-year-old pine tree.
India Today
2 days ago
- India Today
Endocrinologist Dr. Ambrish Mithal on the happy side-effects of weight-loss drugs
New-age weight-loss drugs are exploding the pharmaceutical market, offering better results than traditional medicines. Top endocrinologist Dr. Ambrish Mithal deconstructs the many facets, including side-effects, of these GLP-1 drugs in his recently published book The Weight Loss Revolution, in an episode of India Today's said that while the GLP-1 field -- drugs that belong to the class of GLP-1 targeting the same hormone in the body -- is just beginning to explode, there'll be many newer drugs with less and less side effects and easier to most cases have shown muscle loss as a prominent result of using GLP-1 medications like tirzepatide or semaglutide, Dr. Mithal explains that losing muscle is an accompanying factor to weight loss. "In the long run, if you're not following a healthy diet, you will end up with significant muscle loss. And this is not because of the weight-loss drugs. Whenever we lose weight, we also lose muscle. If you lose 10 kg, you've lost 2-3 kg of muscle. Now, if you want to preserve that, you have to ensure adequate protein and fibre in your diet. Along with that, you have to make sure that you're exercising regularly and that exercise should include strength training," Dr. Mithal also shared what many people experience loose skin after taking these medicines. "When you lose weight rapidly, you lose subcutaneous fat. Particularly in older people where skin tends to sag anyway. If you suddenly lose weight, don't hydrate yourself well, not eating the right kind of balanced diet, then you get that little sagging on the face which people have started calling Ozempic face. Before these drugs came into the market, anyone we put on a very strict diet or someone who had bariatric surgery would see similar results," he gastrointestinal side-effects, nausea, and vomiting, Dr. Mithal addressed concerns about thyroid cancer, highlighting that there's no evidence to link the also explained the "happy side-effects" of GLP-1 medications. Besides growing body of evidence suggesting how semaglutide is linked to Alzheimer's disease, Dr. Mithal said that the benefits of the drugs are moving beyond weight loss."The evidence that they might be helping Alzheimer's by helping obesity in the brain may actually be very exciting, and even for cardiac health, Parkinson's disease. Cardiac events are reduced. Fatty liver is reduced. Kidney disease progression is reduced. But the brain effects are particularly fascinating. Sleep apnea has also gone down," he said, adding that the drugs have also helped improve fertility outcomes in women with PCOS (Polycystic Ovary Syndrome).Currently, most GLP-1 drugs are injectable and expensive, limiting their access in India. However, new formulations and more research are on the way. Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, two blockbuster fat-busting medicines, are set to gain ground in India to tackle the diabetes and obesity crisis."Remember, the GLP-1 field is just beginning to explode. There'll be many newer drugs with less and less side effects and easier to use," Dr. Mithal sayssaid.- EndsMust Watch
Indian Express
2 days ago
- Indian Express
How GLP-1 drugs like semaglutide have revolutionised obesity treatment
Danish pharmaceutical giant Novo Nordisk launched its blockbuster weight-loss injectable semaglutide earlier this week, months after its competitor Eli Lilly's tirzepatide hit Indian markets — and nearly four years after these GLP-1 therapies took the United States by storm. The bottom line is this: these drugs have been shown to be extremely effective for weight-loss, helping people lose 15% to 20% of their body weight, equivalent to what they would otherwise lose with bariatric surgeries. Additionally, they have been found to be effective or are being studied for a host of other conditions, including cardiovascular diseases, kidney disease, non-alcoholic fatty liver disease, and obstructive sleep apnoea. It has also been reported that people on these drugs end up making significant dietary changes, consuming smaller, healthier meals. So how do these 'miracle drugs' work? How were they discovered? And what are other benefits of these drugs? Both semaglutide and tirzepatide belong to a new class of medicines called GLP-1 (glucagon-like peptide-1) receptor agonists. They are prescribed for the management of type-2 diabetes and obesity. These drugs mimic certain naturally-occurring gut hormones called incretins (GLP-1 is one such incretin) produced in the small intestine, and are hence also known as incretin mimicker. They work by: 🔴 improving the secretion of insulin that allows more of the glucose in the bloodstream to enter cells where it can be used for energy; 🔴 inhibiting the secretion of the hormone glucagon that stimulates the liver to release stored glucose into the bloodstream; 🔴 slowing down the emptying of the stomach so that the glucose levels in the bloodstream doesn't spike; and 🔴 reducing appetite by signalling to the brain that one is satiated. Semaglutide and tirzepatide both mimic the action of GLP-1. Tirzepatide additionally also mimics the action of another hormone called glucose-dependent insulinotropic polypeptide (GIP). While incretins were known as early as 1906, research into these gut hormones was overshadowed by the discovery of insulin in 1921. The substance produced by the pancreas has been used to manage diabetes for the past century. Interest in incretins was renewed in the 1960s after several studies showed that oral intake of glucose led to more insulin secretion than intravenously given glucose — demonstrating that the gut makes hormones that regulate insulin and glucose levels. GLP-1 became the first incretin to be discovered in 1986. Trials in the 1990s showed that GLP-1 infusion significantly increased insulin levels and lowered glucose levels in diabetic patients. But there was a problem: GLP-1 was not a very stable compound. This is where Novo Nordisk stepped in. While the pharma giant was primarily looking for a diabetes therapy, researchers believed GLP-1 drugs could also be used to treat obesity given that transplantation of some glucagon-producing tumours in animals caused profound anorexia. Novo Nordisk's first GLP-1 medicine was the daily-injectable liraglutide. Trial participants, however, experienced severe nausea, and when the doses were reduced, the efficacy suffered. But the trials found that nausea could be somewhat mitigated by starting at a lower dose and then gradually titrating up — a method still followed for both semaglutide and tirzepatide. The search for a once-weekly injectable eventually led to the discovery of semaglutide. This also proved to be much more effective than liraglutide for weight loss: those on semaglutide lost up to 15% of their body weight compared to 5% on liraglutide. This led to further clinical trials to look into the drug's weight loss effects. While it was already seeing off-label use for this purpose, semaglutide finally received approval for obesity management from the US regulator in 2021. In addition to the 15% average weight loss, trials with semaglutide have demonstrated its ability to reduce the risk of major cardiovascular events (such as heart attacks and strokes) by 20%, and the risk of all-cause mortality by 19%. Studies have shown a 69% reduction in heart failure events. There is also evidence that the drug can resolve fatty buildup in the liver in 63% of patients and improve liver fibrosis — the hardening of liver tissue due to fatty deposits — in 37% of cases. Tirzepatide, which uses an additional target gastric inhibitory polypeptide (GIP), has been shown to lead to a weight-loss of up to 20% of the body weight. The medicine was also approved for the treatment of obesity-related obstructive sleep apnoea — a condition where a person's breathing stops and starts while they sleep. Trials have also shown that it can improve lipid profile, and demonstrated a 20% reduction in the risk of cardiovascular as well as all cause death. 'There is no doubt that the medicines are effective for kidney and heart conditions. There is also evidence that has emerged about fatty liver disease. But, what I am most excited about are the happy neurological side effects. There seems to be some evidence to show that the medicines are associated with lower risk of Alzheimer's and other dementia,' Dr Ambrish Mithal, chairman of endocrinology and diabetes at Max Healthcare, told The Indian Express. He added: 'Importantly, these drugs have reduced cravings in people. They are not only eating smaller meals but also healthier ones. Sweet cravings have gone down. There is also evidence to show that it helps with alcohol addiction.' Bolstered by the success of semaglutide and tirzepatide, several other drugs are now in the pipeline. 'There are a lot of drugs that are in the pipeline, including drugs with once-a-month dosing instead of every week and very effective oral pills,' Dr Mithal said. Trials are ongoing for drugs such as retatrutide that uses three targets: GLP-1RA and GIP used by its predecessor tirzepatide along with glucagon. There is also CagriSema that uses two targets GLP-1 RA and a new Amylin receptor agonist. Oral GLP-1 drugs such as orforglipron and danulipron may soon be available as well. Two other drugs, which use two targets GLP-1 RA and glucagon — Survodutide and Mazdutide are also in phase 3 clinical trials. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
